$TSRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Trius Therapeutics Inc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Trius Therapeutics Inc. Get notifications about new insider transactions in Trius Therapeutics Inc for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Option Exercise | D | 6.13 | 80,000 | 490,400 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Option Exercise | D | 4.80 | 95,000 | 456,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Option Exercise | D | 3.50 | 50,000 | 175,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Option Exercise | D | 1.29 | 8,138 | 10,498 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Option Exercise | D | 1.29 | 48,837 | 63,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Option Exercise | D | 0.52 | 35,813 | 18,623 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | D | 0.00 | 166,860 | 0 | 0 | 166.9 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | D | 0.00 | 3,230 | 0 | 0 | 3.2 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | EASTHAM KARIN | Director | Option Exercise | D | 7.77 | 15,000 | 116,550 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | EASTHAM KARIN | Director | Option Exercise | D | 5.05 | 12,000 | 60,600 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | EASTHAM KARIN | Director | Option Exercise | D | 8.26 | 12,000 | 99,120 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | EASTHAM KARIN | Director | Option Exercise | D | 3.50 | 6,000 | 21,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | EASTHAM KARIN | Director | Option Exercise | D | 7.57 | 17,441 | 132,028 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | EASTHAM KARIN | Director | Sell | D | 0.00 | 12,114 | 0 | 0 | 12.1 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | EASTHAM KARIN | Director | Sell | D | 0.00 | 6,000 | 0 | 0 | 6 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Schmid John P. | Chief Financial Off ... | Option Exercise | D | 6.13 | 140,000 | 858,200 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Schmid John P. | Chief Financial Off ... | Option Exercise | D | 4.80 | 85,000 | 408,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Schmid John P. | Chief Financial Off ... | Option Exercise | D | 3.50 | 75,000 | 262,500 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Schmid John P. | Chief Financial Off ... | Option Exercise | D | 1.29 | 8,138 | 10,498 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Schmid John P. | Chief Financial Off ... | Option Exercise | D | 1.29 | 28,720 | 37,049 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Schmid John P. | Chief Financial Off ... | Sell | D | 0.00 | 107,639 | 0 | 0 | 107.6 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | O'Leary Brendan | Director | Option Exercise | D | 7.77 | 15,000 | 116,550 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | O'Leary Brendan | Director | Option Exercise | D | 5.05 | 12,000 | 60,600 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | O'Leary Brendan | Director | Option Exercise | D | 8.26 | 12,000 | 99,120 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | O'Leary Brendan | Director | Option Exercise | D | 4.00 | 12,000 | 48,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | O'Leary Brendan | Director | Sell | D | 0.00 | 21,302 | 0 | 0 | 21.3 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | TRUEX PAUL F | Director | Option Exercise | D | 7.77 | 15,000 | 116,550 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | TRUEX PAUL F | Director | Option Exercise | D | 5.05 | 12,000 | 60,600 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | TRUEX PAUL F | Director | Option Exercise | D | 8.26 | 12,000 | 99,120 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | TRUEX PAUL F | Director | Option Exercise | D | 3.50 | 12,000 | 42,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | TRUEX PAUL F | Director | Option Exercise | D | 1.29 | 12,403 | 16,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | TRUEX PAUL F | Director | Sell | D | 0.00 | 11,270 | 0 | 0 | 11.3 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | MORNEAU MICHAEL | VP Finance & CAO | Option Exercise | D | 6.13 | 30,000 | 183,900 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | MORNEAU MICHAEL | VP Finance & CAO | Option Exercise | D | 5.15 | 15,000 | 77,250 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | MORNEAU MICHAEL | VP Finance & CAO | Option Exercise | D | 4.00 | 80,000 | 320,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | MORNEAU MICHAEL | VP Finance & CAO | Sell | D | 0.00 | 14,070 | 0 | 0 | 14.1 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Bartizal Ken | Chief Development O ... | Option Exercise | D | 6.13 | 90,000 | 551,700 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Bartizal Ken | Chief Development O ... | Option Exercise | D | 4.80 | 75,000 | 360,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Bartizal Ken | Chief Development O ... | Option Exercise | D | 3.50 | 40,000 | 140,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Bartizal Ken | Chief Development O ... | Option Exercise | D | 1.29 | 6,395 | 8,250 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Bartizal Ken | Chief Development O ... | Option Exercise | D | 1.29 | 16,569 | 21,374 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Bartizal Ken | Chief Development O ... | Sell | D | 0.00 | 96,400 | 0 | 0 | 96.4 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Prokocimer Philippe | Chief Medical Offic ... | Option Exercise | D | 6.13 | 150,000 | 919,500 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Prokocimer Philippe | Chief Medical Offic ... | Option Exercise | D | 4.80 | 90,000 | 432,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Prokocimer Philippe | Chief Medical Offic ... | Option Exercise | D | 3.50 | 50,000 | 175,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Prokocimer Philippe | Chief Medical Offic ... | Option Exercise | D | 1.29 | 1,744 | 2,250 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Prokocimer Philippe | Chief Medical Offic ... | Option Exercise | D | 1.29 | 16,569 | 21,374 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Prokocimer Philippe | Chief Medical Offic ... | Sell | D | 0.00 | 82,022 | 0 | 0 | 82 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Prokocimer Philippe | Chief Medical Offic ... | Sell | D | 0.00 | 12,190 | 0 | 0 | 12.2 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Stein Jeffrey | President & CEO | Option Exercise | D | 6.13 | 275,000 | 1,685,750 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Stein Jeffrey | President & CEO | Option Exercise | D | 4.80 | 250,000 | 1,200,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Stein Jeffrey | President & CEO | Option Exercise | D | 3.50 | 200,000 | 700,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Stein Jeffrey | President & CEO | Option Exercise | D | 1.29 | 30,813 | 39,749 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Stein Jeffrey | President & CEO | Option Exercise | D | 1.29 | 156,976 | 202,499 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Stein Jeffrey | President & CEO | Option Exercise | D | 0.52 | 81,280 | 42,266 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Stein Jeffrey | President & CEO | Sell | D | 0.00 | 210,457 | 0 | 0 | 210.5 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | KABAKOFF DAVID S | Director | Option Exercise | D | 7.77 | 21,000 | 163,170 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | KABAKOFF DAVID S | Director | Option Exercise | D | 5.05 | 18,000 | 90,900 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | KABAKOFF DAVID S | Director | Option Exercise | D | 8.26 | 18,000 | 148,680 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | KABAKOFF DAVID S | Director | Option Exercise | D | 3.50 | 18,000 | 63,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | KABAKOFF DAVID S | Director | Sell | D | 0.00 | 106,081 | 0 | 0 | 106.1 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | KABAKOFF DAVID S | Director | Sell | D | 0.00 | 5,285 | 0 | 0 | 5.3 K to 0 (-100.00 %) |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Onaitis Matthew | General Counsel | Option Exercise | D | 7.67 | 100,000 | 767,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Fischer Seth H.Z. | Director | Option Exercise | D | 7.77 | 2,500 | 19,425 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Fischer Seth H.Z. | Director | Option Exercise | D | 6.51 | 30,000 | 195,300 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Kjellson Nina S | Director | Option Exercise | D | 7.77 | 15,000 | 116,550 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Kjellson Nina S | Director | Option Exercise | D | 5.05 | 12,000 | 60,600 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Kjellson Nina S | Director | Option Exercise | D | 8.26 | 12,000 | 99,120 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Kjellson Nina S | Director | Option Exercise | D | 3.50 | 12,000 | 42,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Kjellson Nina S | Director | Option Exercise | D | 1.29 | 9,302 | 12,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | ATWOOD BRIAN G | Director | Option Exercise | D | 7.77 | 15,000 | 116,550 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | ATWOOD BRIAN G | Director | Option Exercise | D | 5.05 | 12,000 | 60,600 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | ATWOOD BRIAN G | Director | Option Exercise | D | 8.26 | 12,000 | 99,120 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | ATWOOD BRIAN G | Director | Option Exercise | D | 3.50 | 12,000 | 42,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | ATWOOD BRIAN G | Director | Option Exercise | D | 1.29 | 9,302 | 12,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Schroeder Theodore R | Director | Option Exercise | D | 7.77 | 15,000 | 116,550 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Schroeder Theodore R | Director | Option Exercise | D | 5.05 | 12,000 | 60,600 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Schroeder Theodore R | Director | Option Exercise | D | 8.26 | 12,000 | 99,120 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Schroeder Theodore R | Director | Option Exercise | D | 3.50 | 12,000 | 42,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | Schroeder Theodore R | Director | Option Exercise | D | 7.57 | 15,116 | 114,428 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | THOMPSON JOHN CRAIG | Chief Commercial Of ... | Option Exercise | D | 6.13 | 125,000 | 766,250 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | THOMPSON JOHN CRAIG | Chief Commercial Of ... | Option Exercise | D | 4.80 | 90,000 | 432,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | THOMPSON JOHN CRAIG | Chief Commercial Of ... | Option Exercise | D | 4.30 | 150,000 | 645,000 | 0 | |
| Sep 13 2013 | TSRX | Trius Therapeutics ... | THOMPSON JOHN CRAIG | Chief Commercial Of ... | Sell | D | 0.00 | 2,455 | 0 | 0 | 2.5 K to 0 (-100.00 %) |
| Jul 23 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | S | 12.10 | 1,000 | 12,100 | 166,860 | 167.9 K to 166.9 K (-0.60 %) |
| Jul 16 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | S | 10.55 | 3,500 | 36,925 | 167,860 | 171.4 K to 167.9 K (-2.04 %) |
| Jul 12 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | S | 10.10 | 5,000 | 50,500 | 171,360 | 176.4 K to 171.4 K (-2.84 %) |
| Jul 12 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | S | 9.32 | 500 | 4,660 | 176,360 | 176.9 K to 176.4 K (-0.28 %) |
| Jul 12 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | S | 8.58 | 1,000 | 8,580 | 176,860 | 177.9 K to 176.9 K (-0.56 %) |
| Jul 12 2013 | TSRX | Trius Therapeutics ... | MORNEAU MICHAEL | VP Finance & CAO | Option Exercise | M | 4.00 | 20,000 | 80,000 | 80,000 | |
| Jul 12 2013 | TSRX | Trius Therapeutics ... | MORNEAU MICHAEL | VP Finance & CAO | Sell | S | 9.75 | 20,000 | 195,000 | 12,545 | 32.5 K to 12.5 K (-61.45 %) |
| Jul 12 2013 | TSRX | Trius Therapeutics ... | MORNEAU MICHAEL | VP Finance & CAO | Buy | M | 4.00 | 20,000 | 80,000 | 32,545 | 12.5 K to 32.5 K (+159.43 %) |
| Jul 01 2013 | TSRX | Trius Therapeutics ... | Bartizal Ken | Chief Development O ... | Sell | S | 8.14 | 2,000 | 16,280 | 95,300 | 97.3 K to 95.3 K (-2.06 %) |
| Jul 01 2013 | TSRX | Trius Therapeutics ... | Prokocimer Philippe | Chief Medical Offic ... | Sell | S | 8.14 | 2,000 | 16,280 | 82,022 | 84 K to 82 K (-2.38 %) |
| Jun 12 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | S | 9.08 | 3,000 | 27,250 | 177,860 | 180.9 K to 177.9 K (-1.66 %) |
| Jun 04 2013 | TSRX | Trius Therapeutics ... | Bartizal Ken | Chief Development O ... | Sell | S | 7.90 | 2,000 | 15,800 | 97,300 | 99.3 K to 97.3 K (-2.01 %) |
| Jun 11 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | S | 8.94 | 1,000 | 8,940 | 180,860 | 181.9 K to 180.9 K (-0.55 %) |
| May 23 2013 | TSRX | Trius Therapeutics ... | Kjellson Nina S | Director | Option Exercise | A | 7.77 | 15,000 | 116,550 | 15,000 | |
| Jun 03 2013 | TSRX | Trius Therapeutics ... | Prokocimer Philippe | Chief Medical Offic ... | Sell | S | 7.75 | 2,000 | 15,500 | 84,022 | 86 K to 84 K (-2.32 %) |
| Jun 03 2013 | TSRX | Trius Therapeutics ... | Onaitis Matthew | General Counsel | Option Exercise | A | 7.67 | 100,000 | 767,000 | 100,000 | |
| May 28 2013 | TSRX | Trius Therapeutics ... | Bartizal Ken | Chief Development O ... | Sell | S | 7.93 | 12,000 | 95,119 | 98,927 | 110.9 K to 98.9 K (-10.82 %) |
| May 28 2013 | TSRX | Trius Therapeutics ... | Prokocimer Philippe | Chief Medical Offic ... | Sell | S | 7.93 | 12,000 | 95,119 | 86,022 | 98 K to 86 K (-12.24 %) |
| May 23 2013 | TSRX | Trius Therapeutics ... | Fischer Seth H.Z. | Director | Option Exercise | A | 7.77 | 2,500 | 19,425 | 2,500 | |
| May 23 2013 | TSRX | Trius Therapeutics ... | O'Leary Brendan | Director | Option Exercise | A | 7.77 | 15,000 | 116,550 | 15,000 | |
| May 23 2013 | TSRX | Trius Therapeutics ... | TRUEX PAUL F | Director | Option Exercise | A | 7.77 | 15,000 | 116,550 | 15,000 | |
| May 23 2013 | TSRX | Trius Therapeutics ... | EASTHAM KARIN | Director | Option Exercise | A | 7.77 | 15,000 | 116,550 | 15,000 | |
| May 23 2013 | TSRX | Trius Therapeutics ... | ATWOOD BRIAN G | Director | Option Exercise | A | 7.77 | 15,000 | 116,550 | 15,000 | |
| May 23 2013 | TSRX | Trius Therapeutics ... | Schroeder Theodore R | Director | Option Exercise | A | 7.77 | 15,000 | 116,550 | 15,000 | |
| May 23 2013 | TSRX | Trius Therapeutics ... | KABAKOFF DAVID S | Director | Option Exercise | A | 7.77 | 21,000 | 163,170 | 21,000 | |
| May 16 2013 | TSRX | Trius Therapeutics ... | MORNEAU MICHAEL | VP Finance & CAO | Option Exercise | M | 4.00 | 20,000 | 80,000 | 0 | |
| May 16 2013 | TSRX | Trius Therapeutics ... | MORNEAU MICHAEL | VP Finance & CAO | Sell | S | 7.75 | 20,000 | 155,000 | 10,635 | 30.6 K to 10.6 K (-65.28 %) |
| May 16 2013 | TSRX | Trius Therapeutics ... | MORNEAU MICHAEL | VP Finance & CAO | Buy | M | 4.00 | 20,000 | 80,000 | 30,635 | 10.6 K to 30.6 K (+188.06 %) |
| May 16 2013 | TSRX | Trius Therapeutics ... | Bartizal Ken | Chief Development O ... | Sell | S | 7.85 | 12,000 | 94,200 | 98,927 | 110.9 K to 98.9 K (-10.82 %) |
| May 16 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | S | 8.10 | 5,000 | 40,512 | 181,860 | 186.9 K to 181.9 K (-2.68 %) |
| May 15 2013 | TSRX | Trius Therapeutics ... | Prokocimer Philippe | Chief Medical Offic ... | Sell | S | 7.65 | 12,000 | 91,800 | 86,022 | 98 K to 86 K (-12.24 %) |
| May 14 2013 | TSRX | Trius Therapeutics ... | KPCB PANDEMIC & BIO DEFENSE FU ... | 10% Owner | Sell | J | 0.00 | 680,850 | 0 | 1,697,031 | 2.4 M to 1.7 M (-28.63 %) |
| May 14 2013 | TSRX | Trius Therapeutics ... | KPCB PBD Founders Fund, LLC | 10% Owner | Sell | J | 0.00 | 4,050 | 0 | 10,095 | 14.1 K to 10.1 K (-28.63 %) |
| May 13 2013 | TSRX | Trius Therapeutics ... | Stack Risa | Director | Buy | J | 0.00 | 591 | 0 | 591 | 0 to 591 |
| May 13 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | S | 7.48 | 3,000 | 22,425 | 186,860 | 189.9 K to 186.9 K (-1.58 %) |
| Apr 26 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | S | 7.10 | 500 | 3,550 | 189,860 | 190.4 K to 189.9 K (-0.26 %) |
| Apr 04 2013 | TSRX | Trius Therapeutics ... | Fischer Seth H.Z. | Director | Option Exercise | A | 6.51 | 30,000 | 195,300 | 30,000 | |
| Mar 18 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Sell | S | 7.10 | 1,500 | 10,650 | 190,360 | 191.9 K to 190.4 K (-0.78 %) |
| Mar 11 2013 | TSRX | Trius Therapeutics ... | Schmid John P. | Chief Financial Off ... | Option Exercise | A | 6.13 | 140,000 | 858,200 | 140,000 | |
| Mar 11 2013 | TSRX | Trius Therapeutics ... | THOMPSON JOHN CRAIG | Chief Commercial Of ... | Option Exercise | A | 6.13 | 125,000 | 766,250 | 125,000 | |
| Mar 11 2013 | TSRX | Trius Therapeutics ... | Prokocimer Philippe | Chief Medical Offic ... | Option Exercise | A | 6.13 | 150,000 | 919,500 | 150,000 | |
| Mar 11 2013 | TSRX | Trius Therapeutics ... | MORNEAU MICHAEL | VPF and CAO | Option Exercise | A | 6.13 | 30,000 | 183,900 | 30,000 | |
| Mar 11 2013 | TSRX | Trius Therapeutics ... | Stein Jeffrey | President and CEO | Option Exercise | A | 6.13 | 275,000 | 1,685,750 | 275,000 | |
| Mar 11 2013 | TSRX | Trius Therapeutics ... | Bartizal Ken | Chief Development O ... | Option Exercise | A | 6.13 | 90,000 | 551,700 | 90,000 | |
| Mar 11 2013 | TSRX | Trius Therapeutics ... | Finn John | Chief Scientific Of ... | Option Exercise | A | 6.13 | 80,000 | 490,400 | 80,000 | |
| Jun 25 2012 | TSRX | Trius Therapeutics ... | Schmid John P. | CFO and Secretary | Sell | S | 6.00 | 1,800 | 10,800 | 107,639 | 109.4 K to 107.6 K (-1.64 %) |
| May 24 2012 | TSRX | Trius Therapeutics ... | ATWOOD BRIAN G | Director | Option Exercise | A | 5.05 | 12,000 | 60,600 | 12,000 | |
| May 24 2012 | TSRX | Trius Therapeutics ... | O'Leary Brendan | Director | Option Exercise | A | 5.05 | 12,000 | 60,600 | 12,000 | |
| May 24 2012 | TSRX | Trius Therapeutics ... | EASTHAM KARIN | Director | Option Exercise | A | 5.05 | 12,000 | 60,600 | 12,000 | |
| May 24 2012 | TSRX | Trius Therapeutics ... | Schroeder Theodore R | Director | Option Exercise | A | 5.05 | 12,000 | 60,600 | 12,000 | |
| May 24 2012 | TSRX | Trius Therapeutics ... | Stack Risa | Director | Option Exercise | A | 5.05 | 12,000 | 60,600 | 12,000 | |
| May 24 2012 | TSRX | Trius Therapeutics ... | TRUEX PAUL F | Director | Option Exercise | A | 5.05 | 12,000 | 60,600 | 12,000 | |
| May 24 2012 | TSRX | Trius Therapeutics ... | Kjellson Nina S | Director | Option Exercise | A | 5.05 | 12,000 | 60,600 | 12,000 | |
| May 24 2012 | TSRX | Trius Therapeutics ... | KABAKOFF DAVID S | Director | Option Exercise | A | 5.05 | 18,000 | 90,900 | 18,000 | |
| Mar 29 2012 | TSRX | Trius Therapeutics ... | EASTHAM KARIN | Director | Option Exercise | M | 3.50 | 6,000 | 21,000 | 6,000 | |
| Mar 29 2012 | TSRX | Trius Therapeutics ... | EASTHAM KARIN | Director | Buy | M | 3.50 | 6,000 | 21,000 | 18,114 | 12.1 K to 18.1 K (+49.53 %) |
| Mar 28 2012 | TSRX | Trius Therapeutics ... | O'Leary Brendan | Director | Option Exercise | M | 4.00 | 12,000 | 48,000 | 12,000 | |
| Mar 28 2012 | TSRX | Trius Therapeutics ... | O'Leary Brendan | Director | Option Exercise | M | 1.29 | 9,302 | 12,000 | 0 | |
| Mar 28 2012 | TSRX | Trius Therapeutics ... | O'Leary Brendan | Director | Buy | M | 4.00 | 12,000 | 48,000 | 21,302 | 9.3 K to 21.3 K (+129.00 %) |
| Mar 28 2012 | TSRX | Trius Therapeutics ... | O'Leary Brendan | Director | Buy | M | 1.29 | 9,302 | 12,000 | 9,302 | 0 to 9.3 K |
| Mar 28 2012 | TSRX | Trius Therapeutics ... | Schmid John P. | CFO and Secretary | Option Exercise | M | 1.29 | 5,000 | 6,450 | 28,720 | |
| Mar 28 2012 | TSRX | Trius Therapeutics ... | Schmid John P. | CFO and Secretary | Buy | M | 1.29 | 5,000 | 6,450 | 109,439 | 104.4 K to 109.4 K (+4.79 %) |
| Mar 28 2012 | TSRX | Trius Therapeutics ... | Stein Jeffrey | President and CEO | Option Exercise | M | 0.52 | 38,462 | 20,000 | 81,280 | |
| Mar 28 2012 | TSRX | Trius Therapeutics ... | Stein Jeffrey | President and CEO | Buy | M | 0.52 | 38,462 | 20,000 | 210,457 | 172 K to 210.5 K (+22.36 %) |
| Mar 27 2012 | TSRX | Trius Therapeutics ... | POWELL MICHAEL | Director | Option Exercise | M | 1.29 | 9,302 | 12,000 | 0 | |
| Mar 27 2012 | TSRX | Trius Therapeutics ... | POWELL MICHAEL | Director | Buy | M | 1.29 | 9,302 | 12,000 | 9,302 | 0 to 9.3 K |